Almac Group Achieves Zero Landfill Target
April 22, 2020
Global organisation announces ground-breaking environment milestone just in time for Earth Day
Craigavon, U.K., 22 April 2020 – The global pharmaceutical company, Almac Group, is pleased to announce this Earth Day 2020 that the organisation has achieved a ground-breaking environmental milestone by becoming a zero waste to landfill organisation at its global Headquarter campus in Craigavon. This was achieved by diverting all waste from landfill sites thereby significantly reducing the associated greenhouse gas emissions.
To address the challenge of zero landfill, Almac identified a number of potential outlets for their wasted resources. Subsequently the company commenced a programme to educate key stakeholders about the materials that could be recycled or reused by charities and community organisations.
As a result, recycling and food waste bins were introduced across the Craigavon campus and its 3,500 employees based there encouraged to observe good waste management practices. All waste was either recycled, processed to produce biogas and fertiliser or burned to produce energy.
Wesley Best, Environment Manager at Almac Group, comments on the company’s environmental achievements: “As one of the world’s largest contract pharmaceutical development and manufacturing organisations we were becoming more aware of the environmental impact caused by the needless disposal of waste going to landfill. The process has been carefully orchestrated thanks to the assistance of local contractors, companies and charities, who have helped us achieve our zero-waste goal.
He added: “We are grateful to all our employees who have committed to the initiative and hope that we can lead by example as a company who can make effective steps to prevent landfill waste.”
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.